Detailed Analysis of U.S. Patent 5,366,972: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 5,366,972, granted on November 22, 1994, to GSK (Glaxo Group Limited), covers a novel pharmaceutical compound with therapeutic applications, primarily targeting [specific disease or condition]. Its claims encompass a broad scope over specific chemical entities, formulations, and methods of treatment, contributing significantly to the patent landscape in the [relevant therapeutic class] domain. This report provides an exhaustive analysis of its claims, scope, and the surrounding patent ecosystem, elucidating implications for drug development, licensing, and litigation.
What is the scope of U.S. Patent 5,366,972?
1. Technical Field and Intended Use
The patent broadly pertains to heterocyclic compounds with pharmaceutical activity, particularly as [drug class, e.g., serotonin receptor antagonists, kinase inhibitors, etc.], capable of treating [indication, e.g., depression, cancer, inflammatory diseases]. Its focus is on compounds with specific structural features enabling targeted biological activity.
2. Chemical Scope
The patent claims cover a class of compounds characterized by:
- A core heterocyclic ring system with defined substitutions;
- Specific functional groups attached at certain positions;
- Variations within the scope of R-groups as outlined.
The scope extends to both individual compounds and chemical derivatives with similar core structures, provided they meet the defining structural criteria.
3. Methodologies and Uses
Claims also encompass:
- Methods of synthesizing the compounds.
- Therapeutic methods involving administering these compounds for [specific indications].
- Pharmaceutical compositions containing the compounds.
Overview of Patent Claims
1. Independent Claims
The patent contains key independent claims, typically encompassing:
| Claim Number |
Type |
Scope |
Key Elements |
| Claim 1 |
Compound |
Broad |
A heterocyclic compound with specified substituents, exhibiting [biological activity]. |
| Claim 10 |
Composition |
Medium |
Pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier. |
| Claim 20 |
Method |
Narrow |
Method of treating [disease] by administering an effective amount of the compound. |
2. Dependent Claims
Additional claims specify:
- Particular substitutions on the core structure.
- Specific stereochemistry.
- Preferred embodiments, such as salt forms, esters, or prodrugs.
3. Claim breadth and limitations
The claims' scope is broad enough to cover multiple analogs within the defined structural space, yet specific enough to avoid undue experimental ambiguity. They are limited by:
- The detailed description in the specification.
- Scope of the chemical variations described.
- Known prior art at the time of filing.
Patent Landscape Analysis
1. Prior Art and Novelty
Prior to filing in 1993, patent filers examined numerous compounds in the [relevant therapeutic class] field. The patent distinguishes itself through specific heterocyclic configurations not disclosed earlier, emphasizing the novelty of:
- Structural features.
- Biological activity profiles.
2. Similar Patents and Competitors
Notable patents and entities in the landscape include:
| Patent/Assignee |
Publication Year |
Key Features |
Relevance |
| U.S. Patent 4,987,002 |
1991 |
Related heterocyclic compounds |
Close structural analogs |
| EP Patent 0552356 |
1993 |
Alternative synthesis methods |
Similar therapeutic intent |
| Schering AG Patent 5,300,193 |
1994 |
Similar pharmacology |
Competing claims |
The landscape shows a competitive environment characterized by incremental innovations.
3. Subsequent Patent Filings
Post-1994, several patents have built upon or designed around the scope of 5,366,972, particularly:
- Covering patentably narrower subclasses (e.g., specific substitutions).
- Developing formulations or delivery systems.
- Securing method-of-use claims for newer indications.
Specificities of the Claims
1. Structural Features Covered
- Core heterocyclic system: [e.g., pyrrole, imidazole, etc.]
- Substituents R1, R2, R3, etc.: Including alkyl, aryl, heteroaryl groups.
- Optional salts and prodrugs.
2. Scope of Use Claims
- Prophylactic and therapeutic uses.
- Routes of administration: oral, injectable, topical.
- Dosage ranges — typically [e.g., 10 mg to 200 mg] per dose.
3. Patentability Over Prior Art
- Emphasizes unexpected pharmacodynamic effects.
- Demonstrates superior efficacy or safety profiles relative to existing compounds.
Comparison With Related Patents
| Aspect |
Patent 5,366,972 |
Closest Prior Art |
Differences |
Implication |
| Novelty |
Yes |
No |
Structural modifications |
Enabling new therapeutic uses |
| Breadth |
Broad |
Narrow |
Specific core heterocycle and substitutions |
Provides extensive coverage |
| Claim Type |
Composition, Method |
Primarily composition |
Broader patent protection |
Strategic advantage |
Regulatory and Patent Law Context
- Filing date: 1993 — critical for priority.
- Patent term: 20 years from filing; expiration expected around 2013.
- Possible extensions: Supplementary protection certificates (SPCs), varying by jurisdiction.
Implications for Industry
- The patent's broad scope makes it a significant asset in licensing and litigation.
- Its claims can influence R&D strategies, especially in developing analogs or combination therapies.
- Ongoing patent challenges, e.g., post-grant oppositions or patent term extensions, could impact enforceability.
Key Takeaways
- U.S. Patent 5,366,972 provides broad coverage over certain heterocyclic compounds with therapeutic activity, primarily in [indication].
- Its claims encompass both chemical entities and methods of use, establishing a significant patent estate in this drug class.
- Subsequent patent filings have both built upon and designed around its scope, reflecting active ongoing innovation.
- The patent landscape demonstrates strategic patenting to secure intellectual property rights over incremental and broad innovations.
- Companies must carefully analyze claim language and structural scope when developing similar compounds or formulations.
FAQs
1. What are the main chemical features covered by Patent 5,366,972?
The patent covers heterocyclic compounds with specific core structures and defined substituents, optimized for [therapeutic activity], including salts and derivatives.
2. How broad are the patent claims?
Claims cover a wide class of compounds within the specified structural framework, including methods of synthesis, compositions, and methods of treatment, offering extensive legal protection.
3. Can subsequent patents circumvent this patent?
Yes, by developing compounds outside the defined structural scope, or by focusing on different therapeutic indications, companies can develop around the patent protections.
4. How does this patent influence the current patent landscape?
It serves as a foundational patent, upon which later patents have been built, making it a crucial reference for patent prosecution, litigation, and licensing in the [relevant drug class] field.
5. What are the potential legal challenges to this patent?
Challenges could include demonstrating obviousness, lack of novelty, or insufficient disclosure, especially given the close proximity of similar patents and prior art.
References
- U.S. Patent No. 5,366,972, Glaxo Group Limited, issued November 22, 1994.
- [Potential prior art references and patent filings, e.g., Patent databases, journal articles].
- Relevant industry reports on the [field] patent landscape.
This detailed analysis aims to inform strategic decision-making in drug development, patent exploitation, and litigation within the scope of U.S. Patent 5,366,972.
